Private Label Tranexamic Acid Vitamin C Eye Patch Manufacturer

Are tranexamic acid eye patches FDA-approved or regulated?

By Blake Mereby · Last reviewed October 5, 2026

Tranexamic acid eye patches are cosmetics, not drugs, under US FDA jurisdiction — provided the product is marketed with cosmetic claims only. The FDA does not approve cosmetics before they go to market; instead, it holds brands and manufacturers responsible for the safety and accurate labeling of their products.

A cosmetic claim describes how the product affects appearance: "visibly reduces the look of dark circles," "brightens the under-eye area," or "evens skin tone around the eye." These are permissible cosmetic claims. A drug claim describes a physiological effect on body structure or function: "treats hyperpigmentation," "repairs skin cells," or "inhibits melanin production." Using drug language on a cosmetic product triggers FDA classification as an over-the-counter drug, which requires pre-market approval (via a New Drug Application or OTC monograph compliance) and dramatically changes your regulatory obligations and cost structure.

Under the Modernization of Cosmetics Regulation Act (MoCRA), which became enforceable in late 2023 and into 2024, US cosmetic brands face new requirements: facility registration for domestic manufacturers, product listing with the FDA, and maintenance of safety substantiation records. Importers bringing finished eye patches from a foreign manufacturer must ensure the foreign facility is also registered. MoCRA does not change what is a cosmetic vs. a drug — it adds a compliance layer for all cosmetics.

For the EU, cosmetics are regulated under Regulation (EC) No 1223/2009. Tranexamic acid is not a prohibited or restricted ingredient in the EU at concentrations used cosmetically (typically 1–5%), but you must have a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor before placing the product on the EU market, and the product must be notified in the Cosmetic Products Notification Portal (CPNP). The responsible person (RP) in the EU — a legal entity with an EU address — must be named on the label.

In South Korea, tranexamic acid is classified as a quasi-drug ingredient (기능성화장품) for its skin brightening function, which means Korean-manufactured eye patches with TXA at functional concentrations may require additional registration if you intend to sell domestically in Korea. For export to the US or EU, the Korean factory manufactures to your destination market's standards, so Korean domestic quasi-drug rules do not apply to your product's regulation in the US.

Neither the FDA nor the EU require pre-market approval for your cosmetic eye patches, but both require that you have safety data on file. Budget for a US safety assessment and, if selling in Europe, a full EU CPSR before your first commercial shipment.

Ingredients in this answer: Tranexamic Acid

Read the full guide on Private Label Tranexamic Acid Vitamin C Eye Patch Manufacturer →

More about Private Label Tranexamic Acid Vitamin C Eye Patch Manufacturer

Tell us about your product

Tell us what you're selling and where. You can hire a vetted cosmetic chemist on AJ Cosmo Labs to review your formula and labeling. Starting is free.

Free to start · no credit card · continue in your browser or the iPhone app.

Have a product idea?

Connect with vetted cosmetic chemists and custom labs on AJ Cosmo Labs.

Get on the App Store Open the web app